JOP20220163A1 - مركب بيريدازينيل-ثيازول كربوكساميد - Google Patents

مركب بيريدازينيل-ثيازول كربوكساميد

Info

Publication number
JOP20220163A1
JOP20220163A1 JOP/2022/0163A JOP20220163A JOP20220163A1 JO P20220163 A1 JOP20220163 A1 JO P20220163A1 JO P20220163 A JOP20220163 A JO P20220163A JO P20220163 A1 JOP20220163 A1 JO P20220163A1
Authority
JO
Jordan
Prior art keywords
cancer
antibody
pyridazinyl
activation
compound
Prior art date
Application number
JOP/2022/0163A
Other languages
English (en)
Inventor
Nakamura Akihiko
Ikeda Osamu
Kurosawa Kazuo
Miyasaka Kozo
Okuyama Keiichiro
Watanabe Hideyuki
Tomiyama Hiroshi
Iwai Yoshinori
SEKI Yohei
Original Assignee
Astellas Pharma Inc
Kotobuki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Kotobuki Pharmaceutical Co Ltd filed Critical Astellas Pharma Inc
Publication of JOP20220163A1 publication Critical patent/JOP20220163A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يزود هذا الاختراع مركب مفيد كمكون نشط في تركيب صيدلاني لعلاج السرطان المرتبط بتنشيط الخلايا المناعية أو السرطان الذي لديه مقاومة للعلاج بالأجسام المضادة لـِ PD-1/الأجسام المضادة لـِ PD-L1. ولقد أجرى المخترعون الحاليون دراسات على مركب مفيد كمكون نشط في تركيب صيدلاني لعلاج السرطان المرتبط بتنشيط الخلايا المناعية أو السرطان الذي لديه مقاومة للعلاج بالأجسام المضادة لـِ PD-1/الأجسام المضادة لـِ PD-L1، ووجدوا أن مركب بيريدازينيل-ثيازول كربوكساميد له تأثير مثبط لـِ DGK ? (DGKzeta)، مما أدى إلى انجاز الاختراع الحالي. ويمكن استخدام مركب بيريدازينيل-ثيازول كربوكساميد وفقاً للاختراع الحالي الذي له تأثير مثبط لـِ DGK ?، كعامل علاجي لعلاج السرطان المرتبط بتنشيط الخلايا المناعية أو السرطان الذي لديه مقاومة للعلاج بالأجسام المضادة لـِ PD-1/الأجسام المضادة لـِ PD-L1.
JOP/2022/0163A 2019-12-25 2020-12-24 مركب بيريدازينيل-ثيازول كربوكساميد JOP20220163A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019233673 2019-12-25
PCT/JP2020/048337 WO2021132422A1 (ja) 2019-12-25 2020-12-24 ピリダジニルチアアゾールカルボキシアミド化合物

Publications (1)

Publication Number Publication Date
JOP20220163A1 true JOP20220163A1 (ar) 2023-01-30

Family

ID=76574296

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0163A JOP20220163A1 (ar) 2019-12-25 2020-12-24 مركب بيريدازينيل-ثيازول كربوكساميد

Country Status (21)

Country Link
US (1) US20220315603A1 (ar)
EP (1) EP4083038A4 (ar)
JP (1) JP6948659B1 (ar)
KR (1) KR20220119702A (ar)
CN (3) CN115590854B (ar)
AR (1) AR120896A1 (ar)
AU (1) AU2020413997A1 (ar)
BR (1) BR112022012637A2 (ar)
CA (1) CA3165889A1 (ar)
CL (1) CL2022001752A1 (ar)
CO (1) CO2022009124A2 (ar)
CR (1) CR20220328A (ar)
DO (1) DOP2022000137A (ar)
EC (1) ECSP22057324A (ar)
IL (1) IL294136A (ar)
JO (1) JOP20220163A1 (ar)
MX (1) MX2022007993A (ar)
PE (1) PE20230163A1 (ar)
TW (1) TW202136275A (ar)
WO (1) WO2021132422A1 (ar)
ZA (1) ZA202207543B (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220131918A (ko) 2019-12-24 2022-09-29 카나 바이오사이언스, 인코포레이션 다이아실글리세롤 키나제 조절 화합물
AR120896A1 (es) * 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
EP4139286A1 (en) 2020-04-24 2023-03-01 Bayer Aktiengesellschaft Substituted aminothiazoles as dgkzeta inhibitors for immune activation
WO2022114164A1 (ja) 2020-11-30 2022-06-02 アステラス製薬株式会社 ヘテロアリールカルボキシアミド化合物
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022299051A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN114621214B (zh) * 2022-04-25 2024-04-26 宜春学院 一种抗菌席夫碱n-酰化物及其制备方法和应用
WO2024108100A1 (en) * 2022-11-18 2024-05-23 Incyte Corporation Heteroaryl fluoroalkenes as dgk inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381401B2 (en) * 2004-01-08 2008-06-03 The University Of Chicago T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
AU2006208045B2 (en) * 2005-01-25 2012-08-30 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
CA2639910A1 (en) * 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
EP2009005A4 (en) * 2006-04-19 2010-06-02 Astellas Pharma Inc AZOLECARBOXAMIDE DERIVATIVE
EP2078003B1 (en) * 2006-10-31 2017-03-08 Merck Sharp & Dohme Corp. Anilinopiperazine derivatives and methods of use thereof
PL3814348T3 (pl) * 2018-06-27 2023-09-11 Bristol-Myers Squibb Company Podstawione związki naftyrydynonu przydatne jako aktywatory komórek t
AR120896A1 (es) * 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
WO2022114164A1 (ja) * 2020-11-30 2022-06-02 アステラス製薬株式会社 ヘテロアリールカルボキシアミド化合物

Also Published As

Publication number Publication date
CN115626919A (zh) 2023-01-20
JP6948659B1 (ja) 2021-10-13
EP4083038A1 (en) 2022-11-02
MX2022007993A (es) 2022-07-21
CN113365994A (zh) 2021-09-07
CN115590854A (zh) 2023-01-13
AU2020413997A1 (en) 2022-06-09
CR20220328A (es) 2022-08-30
AR120896A1 (es) 2022-03-30
BR112022012637A2 (pt) 2022-09-06
CL2022001752A1 (es) 2023-03-10
PE20230163A1 (es) 2023-02-01
TW202136275A (zh) 2021-10-01
JPWO2021132422A1 (ja) 2021-12-23
CA3165889A1 (en) 2021-07-01
WO2021132422A1 (ja) 2021-07-01
EP4083038A4 (en) 2023-12-20
KR20220119702A (ko) 2022-08-30
CO2022009124A2 (es) 2022-07-19
US20220315603A1 (en) 2022-10-06
ZA202207543B (en) 2023-12-20
ECSP22057324A (es) 2022-08-31
IL294136A (en) 2022-08-01
DOP2022000137A (es) 2022-11-30
CN115590854B (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
JOP20220163A1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
EP4219563A3 (en) Methods of treating cancer with anti-pd-1 antibodies
MX2022003572A (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
WO2015195848A8 (en) Ezh2 inhibitors for treating lymphoma
EA201690905A1 (ru) Специфические антитела против cd38 для лечения злокачественных новообразований у человека
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
MX2023002507A (es) Inhibidores de cd73.
MX2022015748A (es) Uso de una molecula anti-b7-h3 en combinacion con una molecula anti-pd-1 en la preparacion de formulaciones para el tratamiento de cancer.
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
MX2022005256A (es) Inhibidores de cd73.
PH12016501527A1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MX2022005132A (es) Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
DOP2023000107A (es) Compuesto de heteroarilcarboxamida
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
PH12018502280A1 (en) Tetrahydropyran and thiopyran derivatives having multimodal activity against pain
MX2022007516A (es) Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos.
EA201991302A1 (ru) Комбинированное лечение лекарственными средствами, интерферирующими с нетрином-1 и лекарственными средствами, ингибиторами контрольных точек иммунного ответа
MX2015017124A (es) Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer.
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.